News

Biologics to watch in 2013
Enlarge image

OutlookEUUK

Biologics to watch in 2013

02.01.2013 - At the beginning of the new year, 29 monoclonal antibody (mAbs) drugs are in Phase III clinical development.

While around 350 therapeutic mAbs are currently in clinical development globally, only 28 had entered active Phase 2/3 or Phase 3 studies as of January 2013, according to MABS. Additionally one mAb mixture was under evaluation in Phase III. Historically, mAbs that target antigens relevant to cancer have comprised approximately 50% of the mAb clinical pipeline, but in 2013 the picture has changed: 66% or 19 of the antibodies to watch in 2013 are for non-cancer indications.

The non-cancer mAbs include alirocumab (Regeneron; Sanofi, hypercholesterinemia); AMG 145 (Amgen, hypercholesterinemia), epratuzumab (UCB, SLE), gantenerumab (Roche; Alzheimer’s disease), gevokizumab (Xoma/Servier, Non-infectious uveitis), itolizumab (Biocon, Plaque psoriasis), ixekizumab (Eli Lilly and Co., psoriasis), lebrikizumab (Roche/Genentech, rheumatoid arthritis), mepolizumab (GSK, Asthma, COPD etc.), ocrelizumab (Roche/Genentech, multiple sclerosis), reslizumab (Teva, Eosinophilic asthma), romosozumab (Amgen, Postmenopausal osteoporosis), sarilumab (Regeneron; Sanofi, rheumatoid arthritis), secukinumab (Novartis, rheuma, psoriasis), sirukumab (Janssen R&D LLC, rheumatoid arthritis), solanezumab (Eli Lilly and Co., Alzheimer’s disease), tabalumab (Eli Lilly and Co., rheuma, SLE) and vedolizumab (Millenium, Ulcerative colitis; Crohn disease). The mixture of actoxumab and bezlotoxumab (MK-3415A, Merck & Co.) is being evaluated in two Phase 3 studies as a treatment for Clostridium difficile infection.  

The ten cancer mAbs are: elotuzumab (Bristol-Myers Squibb, Abbott, multiple myeloma), farletuzumab (Morphotek, ovarian cancer), inotuzumab ozogamicin (Pfizer; UCB, ALL, NHL), naptumomab estafenatox (Active Biotech, renal cell carcinoma), necitumumab (ImClone LLC, NSCL), nivolumab (Bristol-Myers Squibb, NSCL, renal cell carcinoma), obinutuzumab (Roche/Genetech, Diffuse large B cell lymphoma, CLL, NHL), onartuzumab (Roche/Genetech, NSCL cancer; gastric cancer), racotumomab (CIMAB; Laboratorio Elea S.A.C.I.F. y A, NSCL), and ramucirumab (ImClone LLC, Gastric; liver, breast, colorectal, NSCL cancers).

© eurobiotechnews.eu/tg

RegulationUKEU

29.07.2014 The first vaccine for malaria may be within reach: The European Medicines Agency has accepted Glaxosmithkline’s malaria vaccine candidate RTS,S for regulatory review.

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M and AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • THERAMETRICS (CH)0.09 CHF12.50%
  • AB SCIENCE (F)11.21 EUR9.37%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.80 EUR268.4%
  • SANTHERA (CH)65.50 CHF81.9%
  • ADDEX (CH)4.01 CHF79.0%

FLOP

  • MERCK KGAA (D)65.21 EUR-48.8%
  • HYBRIGENICS (F)1.74 EUR-28.7%
  • PROSENSA (NL)9.65 USD-23.5%

TOP

  • SANTHERA (CH)65.50 CHF3175.0%
  • GW PHARMACEUTICALS (UK)412.50 GBP630.1%
  • PAION (D)2.74 EUR315.2%

FLOP

  • CYTOS (CH)0.28 CHF-91.8%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.45 EUR-69.7%

No liability assumed, Date: 28.07.2014